Zacks.com on MSN12h
EXEL Tops Q4 Earnings and Sales, Cabometyx Label Expansion in FocusExelixis, Inc. EXEL reported better-than-expected fourth-quarter results. EXEL recorded earnings of 55 cents per share, which beat the Zacks Consensus Estimate of 51 cents. The company registered ...
Functional subpopulations of β-cells emerge to control pulsative insulin secretion in the pancreatic islets of mice through calcium oscillations.
News Medical on MSN22h
New immune map uncovers key pancreatic cancer insightsResearchers determine a complex immune infiltrate pattern based on a newly constructed immune map developed using pancreatic ...
A new blood test could help doctors detect pancreatic cancer earlier, potentially improving survival rates for one of the ...
News Medical on MSN4h
PAC-MANN blood test could help detect pancreatic cancer at early stagesA new blood test could help doctors detect pancreatic cancer earlier, potentially improving survival rates for one of the ...
Phase I clinical trials are the first step in testing a new treatment or combination of treatments. These trials often ...
The test relies on a magnetic nanoparticle linked to fluorescent molecules to detect pancreatic cancer proteins.
The Healthy on MSN17h
“Here’s How I Knew I Had Pancreatic Cancer”: One Survivor’s Story After Years of Growing CluesA pancreatic cancer diagnosis can be startling. One young survivor, who battled this disease during the COVID-19 pandemic, ...
Gene editing is already being used to treat a handful of rare genetic diseases; however, most therapies involve breaking or ...
Exelixis, Inc. (Nasdaq: EXEL) today reported financial results for the fourth quarter and fiscal year of 2024, provided an update on progress toward achieving key ...
More than 67,000 Americans will be diagnosed with pancreatic cancer this year. Learn more about the disease and how PanCAN can help.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback